Canada NewsWire (press release) In February 2013, Cangene acquired all rights to the development of the investigational hemophilia compound IB1001 from Ipsen and Inspiration Biopharmaceuticals Inc. IB1001 is a recombinant Factor IX (rFIX) product being developed for the treatment and ... and more »
Medical Daily ... the National Institutes of Health. Drugs that can curb the cravings associated with alcohol dependence could help people quit the habit. ... The drug blocks the production of steroid hormones that, along with hair growth , are known to impact brain ... and more »
CNBC.com Short-term swings in the stock market don't alter fundamental factors , UBS Chief Investment Strategist Mike Ryan said Thursday. On CNBC's "Fast Money," he ... "Now, in our view, we don't think this fundamentally alters either the trajectory of the Fed ...
Seeking Alpha OGX-225 is a second generation antisense drug candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that when overexpressed affect the growth of cancer cells. Increased IGFBP-2 ...
MarketWatch (press release) The paper's principal investigator, George Cotsarelis, MD, chair of Dermatology in the Perelman School of Medicine at the University of Pennsylvania, and collaborators discovered that fibroblast growth factor 9 (Fgf9), a protein produced by a ... and more »
The Herald | HeraldOnline.com Global Nanotechnology Drug Delivery market to grow at a CAGR of 73.97 percent over the period 2012-2016. One of the key factors contrib...
Bloomberg IGF-1 is an abbreviation for “Insulin-Like Growth Factor -1,” a hormone naturally produced by the human body that is needed for childhood growth , according to the suit. Children suffering from growth failure may be prescribed a drug called Increlex ... and more »
Yahoo! News After researchers determined the disease's molecular structure, they identified the two main classes of enzymes involved in hepatitis C replication: protease and polymerase inhibitors. As a result of that research, direct-acting medications were ...
Wall Street Journal Results "outperformed our plan," said Chief Executive James Dennedy, adding that the firm expects the "solid growth " in hospitality product sales seen in fiscal 2013 to help drive additional growth in fiscal 2014. Amgen Inc. (AMGN, $97.78, -$0.15, -0 ... and more »
Food Business News (registration) In fact, when compared to grocery and drug stores, the convenience channel was the only channel that posted dollar sales and unit sal...
